New late-breaking data highlight abbott structural heart transcatheter valve therapies

Data presented at europcr 2022 reinforce the impact of abbott's minimally invasive heart devices on patient outcomes and quality of life findings demonstrate triclip™ transcatheter edge-to-edge (teer) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies one-year outcomes for navitor™ transcatheter aortic valve implantation (tavi) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis abbott park, ill., may 19, 2022 /prnewswire/ -- abbott (nyse: abt) today announced two late-breaking data presentations highlighting both triclip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and navitor™, the company's latest-generation transcatheter aortic valve implantation (tavi) system.
ABT Ratings Summary
ABT Quant Ranking